Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients

NCT01245582 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Hepatic Neoplasm Malignant

Interventions

DRUG: oxaliplatin (SR96669)
DRUG: capecitabine
DRUG: sorafenib

Sponsor

Sanofi